MRMDOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
MARIMED INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.00 (-3.39%)
Close on Oct 19, 2026
- Market cap
- $22.78M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
36.2%−25.3 pts over 5 years
Operating margin
-1.8%−30.3 pts over 5 years
Net margin
-9.1%−13.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1.3% | +6.0% | +25.7% | +62.2% | |
| Gross profit | -7.6% | -3.3% | +13.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 16.0% | – | – | |
| Return on assets | -3.2% | 3.1% | -7.1% | |
| Current ratio | 0.40 | 0.91 | 1.00 | |
| Net debt to EBITDA | – | 0.47× | – | |
| Interest coverage | -2.7× | 1.5× | -0.4× | |
| Inventory turnover | – | 4.9× | 2.9× | |
| Capex to revenue | 94.4% | 9.2% | 0.7% | |
| Diluted shares | 52M | 324M | 390M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Marimed generated $65.56M from operations and spent $63.27M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$65.56M
Used
$63.27M
Capital expenditure$63.27M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-114.8%
×Asset turnover0.21×
×Equity multiplier1.58×
=Return on equity, FY2018-37.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2018 | -114.8% | 0.21× | 1.58× | -37.4% |
| FY2017 | -19.7% | 0.30× | 3.90× | -22.8% |
| FY2016 | -5.6% | 0.58× | -4.95× | 16.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$14.48M
- Cash generatingOperating cash flow above zero$7.70M
- Return on assets improvedROA up on the prior year-6.4% → -7.0%
- Earnings backed by cashOperating cash flow above net income$7.70M vs -$14.48M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.07 → 1.00
- No dilutionShare count did not rise379M → 390M
- Gross margin improvedGross margin up on the prior year39.70% → 36.22%
- More efficientAsset turnover rose0.80 → 0.77